Back to top
more

Amarin Corporation PLC (AMRN)

(Delayed Data from NSDQ)

$4.96 USD

4.96
7,727,822

+0.03 (0.61%)

Updated Jun 18, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (218 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Amarin (AMRN) Surges: Stock Moves 9% Higher

Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) in Focus: Stock Moves 5.5% Higher

Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $7.03, marking a +1.59% move from the previous day.

Implied Volatility Surging for Amarin (AMRN) Stock Options

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Amarin (AMRN) Gains But Lags Market: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $6.92, marking a +0.58% move from the previous day.

Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

Amarin (AMRN) closed at $6.78 in the latest trading session, marking a +0.89% move from the prior day.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

Amarin (AMRN) closed the most recent trading day at $6.59, moving -1.35% from the previous trading session.

Why Amarin (AMRN) Stock Might be a Great Pick

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $6.68, marking a -1.18% move from the previous day.

Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Amarin's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Amarin.